Singapore markets close in 5 hours 27 minutes

Keros Therapeutics, Inc. (KROS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
51.11+0.68 (+1.35%)
At close: 04:00PM EDT
51.11 0.00 (0.00%)
After hours: 04:01PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close50.43
Open50.65
Bid51.06 x 100
Ask51.47 x 100
Day's range50.03 - 51.58
52-week range27.02 - 73.00
Volume160,791
Avg. volume330,743
Market cap1.844B
Beta (5Y monthly)1.32
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association

    LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that five abstracts will be presented from the KER-050 (elritercept) program at the 29th Annual Congress of the Europ

  • GlobeNewswire

    Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

    LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended March 31, 2024. “Keros remaine

  • GlobeNewswire

    Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

    LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for KER-050 (elritercept) for